Speed is of the essence, so it’s impractical for ENTA to run multiple phase-2 trials that try to answer too many questions. Moreover, the MoA of EDP-235 is well understood, which lessens the potential benefit from gathering mountains of data in phase-2 in order to help de-risk phase-3.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.